Commentary
Commentaries are short perspectives by experts on AJKD articles or nephrology news.
When I was a medical resident, a novel developmental therapy for the treatment of certain cancers was to medically shut off the blood supply and cause ischemia to the mass. Avastin (bevacizumab), or anti-VEGF (vascular endothelial growth factor)
[read more...]Intradialytic hypotension (IDH) is sometimes defined as a decrease in systolic BP by ≥20 mm Hg or a decrease in mean arterial pressure of 10 mm Hg associated with symptoms. There are, however, other definitions of IDH in the literature. Whereas
[read more...]In the United States, approximately 37 million people in the United States have chronic kidney disease (CKD), and in 2016, there were more than 720,000 patients with ESRD on various renal replacement therapies (hemodialysis, peritoneal dialysis, or
[read more...]Membranoproliferative glomerulonephritis (MPGN) is a pattern of glomerular injury on light microscopy that is characterized by mesangial expansion with hypercellularity, endocapillary proliferation, and double-contour formation along the glomerular
[read more...]The identification of APOL1-related kidney disease and recognition of its large contribution to excess risk of end-stage kidney disease (ESKD) in people of West African origin has been one of the biggest stories in nephrology over the past 2 decades
[read more...]There has been significant interest in SGLT2 inhibitors (SGLT2i) as novel oral anti-hyperglycemic agents that have been recently approved for the treatment of type 2 diabetes mellitus (T2DM). Studies such as CANVAS allude to their glucose-lowering
[read more...]Shared decision-making, an approach in which clinicians and patients partner to evaluate best available evidence for treatment options, discuss risks and benefits, and make informed decisions that align with goals and values, is a central tenet of
[read more...]Chronic kidney disease (CKD) is a growing problem worldwide, and as highlighted in NephMadness 2016, there is a relatively new form of CKD of nontraditional etiology in Central America, a nephropathy called mesoamerican nephropathy (MeN). In the
[read more...]What would you think about a drug that has been covered in the New York Times, 60 Minutes, CNN, and Forbes? Surely it’s a blockbuster and cures cancer, prevents heart attacks, or perhaps even prevents kidney failure? However, when you hear that
[read more...]The United States Secretary of Health & Human Services, Alex Azar, recently highlighted in a speech at the National Kidney Foundation’s Kidney Patient Summit the fact that due to misaligned financial incentives, we are paying for kidney
[read more...]
